SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI-210 Autism Clinical Trial

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI-210 Autism Clinical Trial

Publication date: Sep 01, 2026

500 Internal Server Error

Internal Server Error

The server encountered an internal error and was unable to complete your request. Either the server is overloaded or there is an error in the application.

Concepts Keywords
Aug Asd
Autism Autism
Enrollment Cbd
Newswire Clinical
Pharmaceutical Efficacy
Enrollment
Innovative
Israel
Labs
Ltd
Neurothera
Sci
Scisparc
Treatment
Trial

Semantics

Type Source Name
disease MESH Autism
drug DRUGBANK Nonoxynol-9
disease MESH central nervous system disorders
disease MESH autism spectrum disorder
drug DRUGBANK Cannabidiol
disease MESH CBD
drug DRUGBANK Palmidrol
drug DRUGBANK Abacavir

Original Article

(Visited 30 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *